Literature DB >> 15313199

Anthrax toxin complexes: heptameric protective antigen can bind lethal factor and edema factor simultaneously.

Ruth-Anne L Pimental1, Kenneth A Christensen, Bryan A Krantz, R John Collier.   

Abstract

The 83 kDa protective antigen (PA(83)) component of anthrax toxin, after proteolytic activation, self-associates to form ring-shaped heptamers ([PA(63)](7)) that bind and aid delivery of the Edema Factor (EF) and Lethal Factor (LF) components to the cytosol. Here we show using fluorescence (Förster) resonance energy transfer that a molecule of [PA(63)](7) can bind EF and LF simultaneously. We labeled EF and LF with an appropriate donor/acceptor pair and found quenching of the donor and an increase in sensitized emission of the acceptor when, and only when, a mixture of the labeled proteins was combined with [PA(63)](7). Addition of unlabeled PA(63)-binding domain of LF to the mixture competitively displaced labeled EF and LF, causing a loss of energy transfer. In view of the known maximum occupancy of 3 ligand molecules per [PA(63)](7), these findings indicate that PA, EF, and LF can form mixtures of liganded toxin complexes containing both EF and LF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15313199     DOI: 10.1016/j.bbrc.2004.07.105

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel.

Authors:  Sen Zhang; Alan Finkelstein; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-17       Impact factor: 11.205

Review 2.  Membrane translocation by anthrax toxin.

Authors:  R John Collier
Journal:  Mol Aspects Med       Date:  2009-06-27

Review 3.  Obstructing toxin pathways by targeted pore blockage.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Chem Rev       Date:  2012-10-11       Impact factor: 60.622

Review 4.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.

Authors:  Andrei Soliakov; Ian F Kelly; Jeremy H Lakey; Allan Watkinson
Journal:  Eur J Pharm Biopharm       Date:  2011-09-22       Impact factor: 5.571

6.  Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.

Authors:  Benedikt A Aulinger; Michael H Roehrl; John J Mekalanos; R John Collier; Julia Y Wang
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  GRP78(BiP) facilitates the cytosolic delivery of anthrax lethal factor (LF) in vivo and functions as an unfoldase in vitro.

Authors:  Alfred G Tamayo; Louise Slater; Julian Taylor-Parker; Ajit Bharti; Robert Harrison; Deborah T Hung; John R Murphy
Journal:  Mol Microbiol       Date:  2011-07-29       Impact factor: 3.501

8.  Ion conductance of the stem of the anthrax toxin channel during lethal factor translocation.

Authors:  Aviva Schiffmiller; Alan Finkelstein
Journal:  J Mol Biol       Date:  2014-07-01       Impact factor: 5.469

9.  Monitoring the kinetics of the pH-driven transition of the anthrax toxin prepore to the pore by biolayer interferometry and surface plasmon resonance.

Authors:  Subhashchandra Naik; Susan Brock; Narahari Akkaladevi; Jon Tally; Wesley McGinn-Straub; Na Zhang; Phillip Gao; E P Gogol; B L Pentelute; R John Collier; Mark T Fisher
Journal:  Biochemistry       Date:  2013-09-09       Impact factor: 3.162

10.  Peptide Probes Reveal a Hydrophobic Steric Ratchet in the Anthrax Toxin Protective Antigen Translocase.

Authors:  Jennifer M Colby; Bryan A Krantz
Journal:  J Mol Biol       Date:  2015-09-10       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.